A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

NCT02078674 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

610

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza (Pandemic)

Interventions

BIOLOGICAL: Monovalent Avian Influenza VLP (H7N9)
BIOLOGICAL: Matrix-M1™ adjuvant
BIOLOGICAL: Placebo

Sponsor

Novavax

Collaborators

[object Object]